This article has been cited by
1PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice
Kunal Kapoor,Esha Singla,Bijayani Sahu,Amarjit S. Naura
Molecular and Cellular Biochemistry.2015;400(1-2)153
[DOI]
2Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression
Paola Barboro,Nicoletta Ferrari,Matteo Capaia,Andrea Petretto,Sandra Salvi,Simona Boccardo,Cecilia Balbi
International Journal of Cancer.2015;137(7)1574
[DOI]
3Proteomic Characterization of Prostate Cancer to Distinguish Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases
Ann-Kathrin Müller,Melanie Föll,Bianca Heckelmann,Selina Kiefer,Martin Werner,Oliver Schilling,Martin L. Biniossek,Cordula Annette Jilg,Vanessa Drendel
Neoplasia.2018;20(2)140
[DOI]
4Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response
Bijayani Sahu,Arun Narota,Amarjit S. Naura
European Journal of Pharmacology.2020;877(2)173091
[DOI]
5Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population
L A Henríquez-Hernández,A Valenciano,P Foro-Arnalot,M J Álvarez-Cubero,J M Cozar,J F Suárez-Novo,M Castells-Esteve,P Fernández-Gonzalo,B De-Paula-Carranza,M Ferrer,F Guedea,G Sancho-Pardo,J Craven-Bartle,M J Ortiz-Gordillo,P Cabrera-Roldán,J I Rodríguez-Melcón,E Herrera-Ramos,C Rodríguez-Gallego,P C Lara
Prostate Cancer and Prostatic Diseases.2016;19(1)28
[DOI]
6Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer
C Alberti
The British Journal of Radiology.2015;88(1045)20140630
[DOI]
7Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer
A.M. Udager,S.C. Smith,S.A. Tomlins
The British Journal of Radiology.2017;88(1045)271
[DOI]
8“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
Lorena Incorvaia,Francesc Passiglia,Sergio Rizzo,Antonio Galvano,Angela List?,Nadia Barraco,Rossella Maragliano,Valentina Calň,Clara Natoli,Marcello Ciaccio,Viviana Bazan,Antonio Russo
Oncotarget.2017;8(14)23891
[DOI]
9Circulating tumor cells and ?H2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients
Jonathan Chatzkel,Jesse Mocha,Johnna Smith,Jun-Min Zhou,Youngchul Kim,Ghassan El-Haddad,Jingsong Zhang
Future Science OA.2020;6(1)FSO437
[DOI]
10PARP Inhibitors in Prostate Cancer
Praveen Ramakrishnan Geethakumari,Matthew J. Schiewer,Karen E. Knudsen,Wm. Kevin Kelly
Current Treatment Options in Oncology.2017;18(6)FSO437
[DOI]
11PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
Mekonnen Sisay,Dumessa Edessa
Gynecologic Oncology Research and Practice.2017;4(1)FSO437
[DOI]
Feedback

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal